Merck KGaA to Sell U.S. Contract Drug Development and Manufacturing Business
Photo: TokenPost
Merck KGaA has agreed to sell its U.S. contract drug development and manufacturing business to Lonza, expanding the Swiss company’s U.S. network and adding about 1,100 employees. The transaction would increase Lonza’s U.S. CDMO manufacturing site count from four to nine and bring its U.S. workforce above 6,000. It has a total enterprise valuation in the low- to mid-triple-digit millions of Swiss francs. The agreement covers operations in Carlsbad, California; Madison and Verona, Wisconsin; St. Louis, Missouri; and Indianapolis, Indiana. In St. Louis, the sale covers contract drug development and manufacturing bioconjugation operations.
Source: TokenPost
